Medical device company Boston Scientific (NYSE:BSX) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 15.9% year on year to $5.29 billion. The company expects next quarter’s revenue to be around $5.19 billion, close to analysts’ estimates. Its non-GAAP profit of $0.80 per share was 2.4% above analysts’ consensus estimates.
Is now the time to buy BSX? Find out in our full research report (it’s free for active Edge members).
Boston Scientific (BSX) Q4 CY2025 Highlights:
- Revenue: $5.29 billion vs analyst estimates of $5.27 billion (15.9% year-on-year growth, in line)
- Adjusted EPS: $0.80 vs analyst estimates of $0.78 (2.4% beat)
- Adjusted EBITDA: $1.56 billion vs analyst estimates of $1.59 billion (29.5% margin, 2% miss)
- Revenue Guidance for Q1 CY2026 is $5.19 billion at the midpoint, roughly in line with what analysts were expecting
- Adjusted EPS guidance for the upcoming financial year 2026 is $3.46 at the midpoint, in line with analyst estimates
- Operating Margin: 15.6%, in line with the same quarter last year
- Organic Revenue rose 12.7% year on year (beat)
- Market Capitalization: $112 billion
StockStory’s Take
Boston Scientific’s fourth quarter results were met with a significant negative market reaction, despite meeting revenue expectations and delivering adjusted earnings above analyst consensus. Management pointed to broad-based growth, with electrophysiology (EP), WATCHMAN, interventional oncology, and neuromodulation cited as standouts. However, concerns emerged around sequential stagnation in U.S. EP sales and a modest miss in U.S. WATCHMAN, both key franchises for Boston Scientific’s ongoing momentum. CEO Michael Mahoney acknowledged these issues, stating, “We anticipated some share loss in EP given competitive launches, but we remain confident in our above-market growth expectations.”
Looking forward, Boston Scientific’s guidance is supported by expectations of continued outperformance in EP and WATCHMAN, contributions from new product launches, and the anticipated closing of key acquisitions. Management highlighted supply chain improvements in urology and a robust innovation pipeline across multiple product categories. Executive Vice President Jon Monson noted that investments in the global supply chain and the annualization of tariffs could offset some benefits from a favorable product mix, adding, “We expect full year adjusted gross margin to be roughly in line with last year as we continue to invest for growth.”
Key Insights from Management’s Remarks
Management attributed Q4’s results to strong growth in several business units but acknowledged challenges in core franchises and supply chain headwinds, while also highlighting ongoing portfolio diversification and product innovation.
- EP and WATCHMAN performance: Management emphasized strong organic growth in electrophysiology (35%) and WATCHMAN (29%) but faced scrutiny over sequential flatness in U.S. EP and a slight WATCHMAN miss. The company defended its EP market assumptions and stressed ongoing share gains internationally.
- Geographic strength and share shifts: Regional growth was led by the U.S., Japan, and China, with management noting continued share gains outside the U.S. However, Europe’s growth was tempered by product discontinuations, and management expects stronger second-half performance as these issues annualize.
- Portfolio diversification: Boston Scientific cited robust contributions from interventional oncology, neuromodulation, and the recently acquired Nalu Medical, with expectations for these units to drive more growth in 2026 as challenges in urology and endoscopy are addressed.
- Supply chain and product disruptions: The company acknowledged supply chain issues in urology and an AXIOS device removal in endoscopy, which are expected to suppress growth in the first half of the year. Management anticipates recovery as these disruptions are resolved and new launches come to market.
- M&A and pipeline investments: Management highlighted the announced acquisitions of Penumbra and Valencia Technologies, emphasizing their potential to expand Boston Scientific’s presence in key adjacencies and to drive long-term growth through new product introductions and clinical data generation.
Drivers of Future Performance
Management expects revenue and earnings growth to be driven by continued expansion of core franchises, new product launches, and the integration of recent acquisitions, but highlighted margin pressures from tariffs and ongoing investment.
- Innovation pipeline and clinical data: Management expects new product launches, including the FARAPOINT PFA catheter and advancements in coronary and oncology therapies, to drive growth. The upcoming CHAMPION trial results for WATCHMAN could significantly expand its addressable market if positive.
- Operational and supply chain execution: The company is focused on resolving supply chain and product disruption issues in urology and endoscopy, aiming for improved performance in these segments as the year progresses.
- Margin and cost headwinds: While a favorable product mix and operational leverage are expected to support margins, management cautioned that investments in global supply chain capacity and the impact of tariffs will offset some gains, keeping adjusted gross margin roughly flat year over year.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be closely monitoring (1) the rollout and adoption of new EP and WATCHMAN product iterations, (2) resolution of supply chain and product disruptions in urology and endoscopy, and (3) the integration and performance of recent acquisitions, particularly Penumbra and Valencia Technologies. The outcome of the CHAMPION trial and progress on clinical studies in coronary and oncology therapies will also be crucial signposts for sustained growth.
Boston Scientific currently trades at $77.01, down from $91.62 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
High Quality Stocks for All Market Conditions
The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.